Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2725679 | The American Journal of Medicine | 2009 | 14 Pages |
Abstract
This article aims to provide an overview of efficacy and safety data on glucagon-like peptide–1 (GLP-1) receptor agonists and dipeptidyl peptidase–4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Matthew P. Gilbert, Richard E. Pratley,